XRCC3 Thr241Met polymorphism and clinical outcomes of NSCLC patients receiving platinum-based chemotherapy: a systematic review and meta-analysis.
<h4>Introduction</h4>X-ray repair cross-complementing protein 3 (XRCC3) is an essential gene involved in the double-strand break repair pathway. Published evidence has shown controversial results about the relationship between XRCC3 Thr241Met polymorphism and clinical outcomes of non-sma...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2013-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0069553 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849427337487056896 |
|---|---|
| author | Xiao-yong Shen Fan-zhen Lu Yun Wu Li-ting Zhao Zhi-feng Lin |
| author_facet | Xiao-yong Shen Fan-zhen Lu Yun Wu Li-ting Zhao Zhi-feng Lin |
| author_sort | Xiao-yong Shen |
| collection | DOAJ |
| description | <h4>Introduction</h4>X-ray repair cross-complementing protein 3 (XRCC3) is an essential gene involved in the double-strand break repair pathway. Published evidence has shown controversial results about the relationship between XRCC3 Thr241Met polymorphism and clinical outcomes of non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy.<h4>Methods</h4>A systematic review and meta-analysis was performed to evaluate the predictive value of XRCC3 Thr241Met polymorphism on clinical outcomes of advanced NSCLC receiving platinum-based chemotherapy. Response to chemotherapy, overall survival (OS) and progression-free survival (PFS) were analyzed.<h4>Results</h4>A number of 11 eligible studies were identified according to the inclusion criteria. Carriers of the variant XRCC3 241Met allele were significantly associated with good response to platinum-based chemotherapy (ThrMet/MetMet vs. ThrThr: OR = 1.509, 95% CI: 1.099-2.072, Pheterogeneity = 0.618). The XRCC3 Thr241Met polymorphism was not associated with OS (MetMet vs. ThrThr, HR = 0.939, 95% CI:0.651-1.356, Pheterogeneity = 0.112) or PFS (MetMet vs. ThrThr, HR = 0.960, 95% CI: 0.539-1.710, Pheterogeneity = 0.198). Additionally, no evidence of publication bias was observed.<h4>Conclusions</h4>This systematic review and meta-analysis shows that carriers of the XRCC3 241Met allele are associated with good response to platinum-based chemotherapy in advanced NSCLC, while the XRCC3 Thr241Met polymorphism is not associated with OS or PFS. |
| format | Article |
| id | doaj-art-cd771b0274734e2cbbc9c842d53e5638 |
| institution | Kabale University |
| issn | 1932-6203 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-cd771b0274734e2cbbc9c842d53e56382025-08-20T03:29:04ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0188e6955310.1371/journal.pone.0069553XRCC3 Thr241Met polymorphism and clinical outcomes of NSCLC patients receiving platinum-based chemotherapy: a systematic review and meta-analysis.Xiao-yong ShenFan-zhen LuYun WuLi-ting ZhaoZhi-feng Lin<h4>Introduction</h4>X-ray repair cross-complementing protein 3 (XRCC3) is an essential gene involved in the double-strand break repair pathway. Published evidence has shown controversial results about the relationship between XRCC3 Thr241Met polymorphism and clinical outcomes of non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy.<h4>Methods</h4>A systematic review and meta-analysis was performed to evaluate the predictive value of XRCC3 Thr241Met polymorphism on clinical outcomes of advanced NSCLC receiving platinum-based chemotherapy. Response to chemotherapy, overall survival (OS) and progression-free survival (PFS) were analyzed.<h4>Results</h4>A number of 11 eligible studies were identified according to the inclusion criteria. Carriers of the variant XRCC3 241Met allele were significantly associated with good response to platinum-based chemotherapy (ThrMet/MetMet vs. ThrThr: OR = 1.509, 95% CI: 1.099-2.072, Pheterogeneity = 0.618). The XRCC3 Thr241Met polymorphism was not associated with OS (MetMet vs. ThrThr, HR = 0.939, 95% CI:0.651-1.356, Pheterogeneity = 0.112) or PFS (MetMet vs. ThrThr, HR = 0.960, 95% CI: 0.539-1.710, Pheterogeneity = 0.198). Additionally, no evidence of publication bias was observed.<h4>Conclusions</h4>This systematic review and meta-analysis shows that carriers of the XRCC3 241Met allele are associated with good response to platinum-based chemotherapy in advanced NSCLC, while the XRCC3 Thr241Met polymorphism is not associated with OS or PFS.https://doi.org/10.1371/journal.pone.0069553 |
| spellingShingle | Xiao-yong Shen Fan-zhen Lu Yun Wu Li-ting Zhao Zhi-feng Lin XRCC3 Thr241Met polymorphism and clinical outcomes of NSCLC patients receiving platinum-based chemotherapy: a systematic review and meta-analysis. PLoS ONE |
| title | XRCC3 Thr241Met polymorphism and clinical outcomes of NSCLC patients receiving platinum-based chemotherapy: a systematic review and meta-analysis. |
| title_full | XRCC3 Thr241Met polymorphism and clinical outcomes of NSCLC patients receiving platinum-based chemotherapy: a systematic review and meta-analysis. |
| title_fullStr | XRCC3 Thr241Met polymorphism and clinical outcomes of NSCLC patients receiving platinum-based chemotherapy: a systematic review and meta-analysis. |
| title_full_unstemmed | XRCC3 Thr241Met polymorphism and clinical outcomes of NSCLC patients receiving platinum-based chemotherapy: a systematic review and meta-analysis. |
| title_short | XRCC3 Thr241Met polymorphism and clinical outcomes of NSCLC patients receiving platinum-based chemotherapy: a systematic review and meta-analysis. |
| title_sort | xrcc3 thr241met polymorphism and clinical outcomes of nsclc patients receiving platinum based chemotherapy a systematic review and meta analysis |
| url | https://doi.org/10.1371/journal.pone.0069553 |
| work_keys_str_mv | AT xiaoyongshen xrcc3thr241metpolymorphismandclinicaloutcomesofnsclcpatientsreceivingplatinumbasedchemotherapyasystematicreviewandmetaanalysis AT fanzhenlu xrcc3thr241metpolymorphismandclinicaloutcomesofnsclcpatientsreceivingplatinumbasedchemotherapyasystematicreviewandmetaanalysis AT yunwu xrcc3thr241metpolymorphismandclinicaloutcomesofnsclcpatientsreceivingplatinumbasedchemotherapyasystematicreviewandmetaanalysis AT litingzhao xrcc3thr241metpolymorphismandclinicaloutcomesofnsclcpatientsreceivingplatinumbasedchemotherapyasystematicreviewandmetaanalysis AT zhifenglin xrcc3thr241metpolymorphismandclinicaloutcomesofnsclcpatientsreceivingplatinumbasedchemotherapyasystematicreviewandmetaanalysis |